Loading stock data…
Denali Therapeutics Inc. (DNLI)
$23.11-0.31 (-1.32%)
Market ClosedLast close Jul 24
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Denali Therapeutics Inc. in the Healthcare sector is trading at $23.11 with a market capitalization of $3.1B. Wall Street consensus targets $34.31 (16 analysts), implying a +48.5% move over the next 12 months. The stock is currently 15% below its 52-week high of $27.30, remaining 17.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +48.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$137.36M | -$137.37M | -$137.43M↓ | -$134.96M↑ | -$145.58M |
| Net Income | -$128.45M | -$128.55M↓ | -$126.90M↓ | -$124.12M↑ | -$132.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflamma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.86%
Volume
Today's trading volume
1.13M
Recent News
Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey?
Denali Therapeutics (DNLI) is scheduled to present at the Alzheimer’s Association International Conference in London on July 12, 2026, where CEO Ryan J. Watts will be speaking. The event is drawing renewed attention to the stock. See our latest analysis for Denali Therapeutics. The upcoming AAIC presentation sits against a backdrop where Denali Therapeutics’ share price has climbed 45.30% year to date and its 1 year total shareholder return of 63.37% contrasts with weaker 3 and 5 year total...
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval?
Denali Therapeutics stock has delivered a 71.8% return over the past year, yet current valuation checks suggest the shares are trading at a premium, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to an overvalued picture. A 71.8% one year return sets a high bar for future expectations and can leave less room for disappointment in the share price. The recent FDA approval of Avlayah and positive analyst coverage may support higher revenue...
Beyond weight loss: Lilly aims for leadership in brain science
Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first
Slate Medicines Appoints Mark W. Hahn to Board of Directors
By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.